Govt panel recommends against allowing SII to conduct Covovax trial on children aged 2-17 yrs

On Wednesday, an expert panel of India's central drug authority recommended against granting permission to the Serum Institute of India (SII) to conduct the phase 2/3 trial of COVID-19 vaccine Covovax on children aged two to 17 years, sources said. The SII applied to the Drugs Controller General of India (DCGI) on Monday seeking permission to conduct a trial of…
« Previous post: | Next post: »